NCT02657876View on ClinicalTrials.gov

ExpressGraft-C9T1 Skin Tissue as a Treatment of Diabetic Foot Ulcers

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

May 28, 2019

Study Completion Date

May 28, 2019

Conditions
DiabetesDiabetic Foot UlcerNon-healing Wound
Interventions
BIOLOGICAL

ExpressGraft-C9T1 Skin Tissue

ExpressGraft-C9T1 skin tissue is provided as a suturable, biologically-active, circular skin tissue with a fully-stratified epithelial compartment comprised of human keratinocytes (NIKSC9T1) and a dermal compartment containing fibroblasts

Trial Locations (1)

15222

SerenaGroup Research Institute, Pittsburgh

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Stratatech, a Mallinckrodt Company

INDUSTRY

NCT02657876 - ExpressGraft-C9T1 Skin Tissue as a Treatment of Diabetic Foot Ulcers | Biotech Hunter | Biotech Hunter